• Introduction:

    I am dual-trained in both Medical Hematology/Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago. My specialty training allowed me to develop expertise in clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. In September 2015, I joined the faculty at the University of Alabama at Birmingham as an Assistant Professor of Medicine.

    Clinical Interests & Research:

    My focus remains in highly aggressive women’s malignancies (i.e. triple-negative and HER2+ breast cancer as well as high-grade serous ovarian cancer) and early-phase clinical trial design. In this role, I serve as a clinician-scientist helping laboratory-based scientist translate laboratory findings to the clinical setting by designing trials.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancerOncogene.  41:268-279. 2022
    2022 Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients 2022
    2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerBreast Cancer Research.  23. 2021
    2021 Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancernpj Breast Cancer.  7. 2021
    2021 First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumorsClinical Cancer Research.  27:4511-4520. 2021
    2021 Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)European journal of cancer.  153:223-233. 2021
    2021 Disparities in Breast Cancer Associated With African American Identity.American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  41:e29-e46. 2021
    2021 Breast cancer, version 4.2021 featured updates to the NCCN guidelines 2021
    2020 Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical TrialJAMA Oncology.  6:1355-1362. 2020
    2020 Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncology.  6:676-684. 2020
    2020 Breast cancer, version 3.2020 2020
    2020 MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trialJournal of Clinical Oncology.  38:1059-1069. 2020
    2019 Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology.  5:1141-1149. 2019
    2018 Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerSurgical Clinics of North America.  98:773-785. 2018
    2017 MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerBreast Cancer Research.  19. 2017
    2016 A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSpringerPlus.  5. 2016
    2015 Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinomaGynecologic Oncology.  138:656-662. 2015


    Year Title Altmetric
    2014 Chemotherapy and/or targeted therapies for advanced endometrial cancer: Time to rethink?.  59-68. 2014

    Research Overview

  • Breast Cancer
    Ovarian Cancer
    Developmental Therapeutics
    Translational Research
  • Education And Training

  • Tulane University, Internship
  • Baptist Health System, Residency
  • University of Chicago, Postdoctoral Fellowship
  • University of Chicago, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Alabama 2008
  • Bachelor of Science or Mathematics in Biomedical Sciences, Auburn University 2004
  • Full Name

  • Erica Stringer-Reasor